|
Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma Clinical research trials and Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma. Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma clinical trial. Test subjects typically obtain the finest healthcare available for their Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma  Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma
Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma
For Condition: adult infiltrating astrocytoma
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , North Central Cancer Treatment Group
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of procarbazine, lomustine, and vincristine followed by radiation therapy in treating adults who have supratentorial glioma.
Details: OBJECTIVES: I. Estimate the response rate of patients with newly diagnosed supratentorial low-grade glioma following neoadjuvant chemotherapy with PCV (procarbazine/lomustine/vincristine). II. Describe the toxicity of PCV. III. Determine the incidence of disease progression in these patients during PCV treatment. PROTOCOL OUTLINE: The following acronyms are used: CCNU Lomustine, NSC-79037 PCB Procarbazine, NSC-77213 PCV PCB/CCNU/VCR VCR Vincristine, NSC-67574 3-Drug Combination Chemotherapy Followed by Radiotherapy. PCV; followed by external-beam cranial irradiation using at least 6 MV photons. PROJECTED ACCRUAL: This study will accrue a maximum of 61 patients within 5 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed supratentorial * grade I/II glioma, including: Diffuse fibrillary astrocytoma; No pilocytic astrocytoma; No mixed tumor with ependymoma elements - Supratentorial sites include: Frontal, temporal, parietal, or occipital lobes; Thalamus, basal ganglia, or midbrain; Lateral or third ventricles; Pons, medulla, or optic chiasm tumors allowed only if secondary to eligible tumor - More than 1 separate tumor allowed - Diagnosis based on surgical biopsy or subtotal resection - Measurable or evaluable disease on T2-weighted MRI required --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No prior chemotherapy - Endocrine therapy: At least 1 week since prior steroids OR Stable steroid dose for at least 1 week prior to study - Radiotherapy: No prior cranial or head and neck irradiation - Surgery: See Disease Characteristics --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-2 - Hematopoietic: WBC greater than 3,500/mm3; Platelet count greater than 130,000/mm3; Hemoglobin greater than 9 g/dL - Hepatic: Bilirubin less than 2 times upper limit of normal (ULN); AST less than 2 times ULN; Alkaline phosphatase less than 2 times ULN - Renal: Creatinine less than 1.5 times ULN - Other: No active or uncontrolled infection; No second malignancy within 3 years except: Nonmelanomatous skin cancer In situ cervical cancer; No pregnant or nursing women; Negative pregnancy test required within 7 days prior to entry; Effective contraception required of fertile patients
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JanBuckner, Study Chair, North Central Cancer Treatment Group
CCOP - Merit Care Hospital
Fargo, North Dakota, 58122
United States
CCOP - Cedar Rapids Oncology Project
Cedar Rapids, Iowa, 52403-1206
United States
CCOP - Geisinger Clinical and Medical Center
Danville, Pennsylvania, 17822-2001
United States
Rapid City Regional Hospital
Rapid City, South Dakota, 57709
United States
CCOP - Scottsdale Oncology Program
Scottsdale, Arizona, 85259-5404
United States
Altru Health Systems
Grand Forks, North Dakota, 58201
United States
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
United States
CCOP - Duluth
Duluth, Minnesota, 55805
United States
Quain & Ramstad Clinic, P.C.
Bismark, North Dakota, 58501
United States
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309-1016
United States
Siouxland Hematology-Oncology
Sioux City, Iowa, 51101-1733
United States
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio, 43623-3456
United States
CCOP - Wichita
Wichita, Kansas, 67214-3882
United States
CCOP - Metro-Minnesota
St. Louis Park, Minnesota, 55416
United States
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
United States
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota, 57105-1080
United States
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
United States
Additional Information:
Study ID Numbers: CDR0000064910; NCCTG-937202
Study Start Date: July 1996
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002806
Other Adult Infiltrating Astrocytoma Studies:
1. Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
2. Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
3. Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
4. Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
5. Imatinib Mesylate in Treating Patients With Gliomas
Related Studies:
Other adult infiltrating astrocytoma Clinical Trials
Other South Dakota Clinical Trials
Other Rapid City Clinical Trials
Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma
|
|
|
|
|
|
|
|
